Sponsors planning a clinical trial that spans more than one African country have historically had to treat each national regulator as a separate, unrelated approval process — with review timelines that, across the continent’s roughly 54 jurisdictions, have ranged from about 60 days to well over a year for the same dossier. The African Medicines Agency (AMA) is the African Union’s answer to that fragmentation: a continental specialized health agency intended to coordinate joint scientific review and harmonize regulatory standards across member states, not to replace national regulators outright. This guide covers what AMA actually is, what it does and doesn’t do yet, and what it practically means for sponsors and research administrators planning multi-country African trials today.
What Is the African Medicines Agency?
The AMA Treaty was adopted by the African Union Assembly in February 2019 and entered into force on 5 November 2021, once the 15th AU member state ratified it — the threshold the treaty itself set for the agency to come into legal existence. AMA builds on more than a decade of prior work by the African Medicines Regulatory Harmonization (AMRH) initiative, run under the African Union Development Agency (AUDA-NEPAD), which piloted joint and reliance-based review mechanisms at the regional level (for example through the East African Community Medicines Regulatory Harmonization program) before AMA existed as a standalone treaty body.
AMA’s physical headquarters, in Kigali, Rwanda, was formally inaugurated on 1 November 2024 by the African Union and the Government of Rwanda — a milestone in the agency’s build-out, but a distinct event from the treaty’s 2021 entry into force. As of the HQ inauguration and the activation work that has continued since, AMA has been in an active operational build-out phase: standing up staffing, governance structures, and pilot review procedures rather than functioning yet as a single point of approval that displaces national agencies.
The Problem AMA Is Meant to Solve: Timelines From 60 Days to Over a Year
The core operational pain point AMA targets is regulatory fragmentation. Because each African country runs its own independent clinical trial authorization process, sponsors running the same protocol across several countries have faced review timelines ranging from roughly 60 working days in faster-moving jurisdictions to more than a year in others, with no shared dossier format or mutual recognition between most national regulators. Regional harmonization pilots that pre-date and now feed into AMA’s joint review mechanisms have shown what coordination can do to that range: the East African Community’s medicines regulatory harmonization program, for instance, has been reported to cut median review times roughly in half through shared assessment procedures. AMA’s mandate is to extend that kind of coordination continent-wide rather than leaving it to ad hoc regional blocs.
AMA’s Mandate: Joint Review for Vaccines, Biosimilars, and API Manufacturing
AMA’s founding mandate specifically includes coordinating joint scientific review of clinical trial applications and marketing authorization dossiers for vaccines and other products the treaty describes as scientifically complex, including biosimilars — categories where a single centralized technical assessment can be shared across multiple participating countries instead of being duplicated at each national agency. The mandate also covers joint inspections of active pharmaceutical ingredient (API) manufacturing sites, and a broader remit to strengthen pharmacovigilance oversight across the continent. In practice, this mechanism has grown out of the AMRH’s earlier joint-review pilots, which AMA is intended to formalize and scale, rather than starting from nothing.
It’s worth being precise about what this does and doesn’t mean for a sponsor today: AMA’s joint review is a coordination layer that sits above national authorization, aimed at the specific product categories and multi-country scenarios named in its mandate. It is not, at this stage, a single continental IND-equivalent that substitutes for every national clinical trial application — most trials still require country-by-country submission through each participating national regulator.
How AMA Is Being Built Out: Kigali and EU/EMA Support
Standing up a new continental regulatory agency from a treaty to a functioning technical body takes sustained institutional investment. On 26 January 2024, the European Medicines Agency (EMA) announced a €10 million grant from the European Commission, committed over roughly five years through 2027, specifically to support AMA’s establishment. That funding is directed at scientific and regulatory capacity-building — training AMA and AU member-state assessors, and supporting AMRH’s pilot procedures for joint continental evaluation of medicines — rather than at AMA’s physical infrastructure, which has been funded separately (the Kigali headquarters itself was established with support from Rwanda and the African Union). This EU/EMA support sits within a longer pattern of European ‘Team Europe’ funding for African medicines regulatory harmonization that predates AMA’s 2021 entry into force.
What This Means for Sponsors Planning Multi-Country African Trials
- Plan for national submissions as the near-term default. Until AMA’s joint review mechanisms are fully operational and adopted by a given set of countries, the safest planning assumption is that each participating country’s national regulator — for example Nigeria’s NAFDAC or Egypt’s EDA — remains the actual approval authority for your trial in that jurisdiction. See CASRAI’s guides to the NAFDAC pathway in Nigeria and the EDA pathway in Egypt for what that looks like in practice at the country level.
- Ask early whether your product category qualifies for joint review. If your trial involves a vaccine or a product AMA classifies as scientifically complex (biosimilars are the explicit example in AMA’s mandate), find out whether the countries in your trial footprint are participating in an active AMA/AMRH joint review pilot before defaulting to fully separate national submissions — this is where AMA’s coordination is furthest along.
- Budget timeline variability into your project plan. Until harmonization matures across more countries and product categories, treat the historical 60-days-to-over-a-year range as the realistic planning envelope for country-by-country approval, not the shorter, harmonized timeline AMA is working toward.
- Don’t assume AMA review replaces site-level ethics review. AMA’s mandate is a national/regulatory-agency-level coordination function; informed consent and research ethics committee (REC) or IRB-equivalent review remain jurisdiction- and site-specific regardless of any joint regulatory review your product receives.
- Track AMA’s own published guidance directly. As a young institution still building out its technical procedures, AMA’s actual scope of joint review is likely to expand faster than secondary sources can reliably summarize — check ama.au.int and AUDA-NEPAD’s AMRH pages for the current list of participating countries and product categories before finalizing a regulatory strategy.
AMA and National Regulators: Coordination, Not Replacement
It’s easy to over-read ‘continental medicines agency’ as a single unified approval body along the lines of the U.S. FDA. AMA’s actual design is closer to the EMA’s relationship with individual EU member-state agencies before full centralization matured — a coordinating and harmonizing layer that works through and alongside national regulators rather than displacing them. For a useful structural comparison of how a centralized-versus-national regulatory model actually differs in practice, see CASRAI’s EMA vs. FDA comparison. For sponsors, this means the practical unit of regulatory work for the foreseeable future remains the national dossier — informed by, and increasingly able to draw on, whatever joint review AMA has activated for a given product and country set. Site-level operational planning, including clinical trial site selection and feasibility assessment, should continue to be built around each country’s actual current regulatory pathway rather than an assumption of continent-wide harmonization that hasn’t yet arrived.
Frequently Asked Questions
What is the African Medicines Agency (AMA)?
AMA is a specialized health agency of the African Union established by treaty to coordinate medicines regulation across AU member states — including joint scientific review of certain clinical trial applications and marketing authorization dossiers, joint inspection of API manufacturing sites, and continent-wide pharmacovigilance strengthening.
When was AMA established — and is that the same as when it became operational?
No. The AMA Treaty was adopted by the AU Assembly in February 2019 and legally entered into force on 5 November 2021, after the 15th member state ratified it. Its headquarters in Kigali, Rwanda was formally inaugurated later, on 1 November 2024, and the agency has continued building out full operational capacity since.
Does AMA replace national regulators like NAFDAC, the EDA, or SAHPRA for clinical trial approval?
No. AMA is designed to coordinate and harmonize, not to substitute for national regulatory authorization. For the foreseeable future, sponsors should expect to still submit through each country’s own national regulator for most trials, with AMA’s joint review mechanisms applying to specific product categories and participating countries.
How does AMA aim to harmonize Africa’s wide range of clinical trial approval timelines?
Historical national approval timelines across Africa have ranged from roughly 60 days to over a year for comparable dossiers. AMA’s joint scientific review mechanism, built on regional harmonization pilots such as the East African Community’s program, is intended to let multiple countries share a single technical assessment instead of duplicating it — the kind of coordination that regional pilots have already shown can substantially cut review times.
What products does AMA’s joint review currently cover?
AMA’s mandate specifically names vaccines and scientifically complex products such as biosimilars for joint clinical trial and marketing authorization review, plus joint inspection of active pharmaceutical ingredient (API) manufacturing sites. It is not a general-purpose replacement for every national trial application.
Who funds AMA, and what does the EU’s involvement cover?
AMA is funded primarily by AU member states, with international partners contributing to specific capacity-building. The European Medicines Agency announced a €10 million European Commission grant in January 2024, committed over roughly five years through 2027, aimed at scientific and regulatory training support and joint-review pilot procedures rather than at AMA’s physical infrastructure.
